Biological and clinical implications of cancer stem cells in primary brain tumors

Marcello Maugeri-Saccà, Simona Di Martino, Ruggero De Maria

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Despite therapeutic advances, glioblastoma multiforme (GBM) remains a lethal disease. The infiltrative nature of this disease and the presence of a cellular population resistant to current medical treatments account for the poor prognosis of these patients. Growing evidence indicates the existence of a fraction of cancer cells sharing the functional properties of adult stem cells, including self-renewal and a greater ability to escape chemo-radiotherapy-induced death stimuli. Therefore, these cells are commonly defined as cancer stem cells (GBM-SCs). The initial GBM-SC concept has been challenged, and refined according to the emerging molecular taxonomy of GBM. This allowed to postulate the existence of multiple CSC types, each one driving a given molecular entity. Furthermore, it is becoming increasingly clear that GBM-SCs thrive through a dynamic and bidirectional interaction with the surrounding microenvironment. In this article, we discuss recent advances in GBM-SC biology, mechanisms through which these cells adapt to hostile conditions, pharmacological strategies for selectively killing GBM-SCs, and how novel CSC-associated endpoints have been investigated in the clinical setting.

Original languageEnglish
Article numberArticle 00006
JournalFrontiers in Oncology
Volume3 JAN
DOIs
Publication statusPublished - 2013

Fingerprint

Neoplastic Stem Cells
Glioblastoma
Brain Neoplasms
Adult Stem Cells
Radiotherapy
Pharmacology
Therapeutics
Population
Neoplasms

Keywords

  • Cancer stem cells
  • Canonical pathway inhibitors
  • Chemo-radioresistance
  • Differentiation-inducing agents
  • Glioblastoma multiforme
  • Hypoxia
  • Self-renewal pathway inhibitors
  • Stem cell-based endpoints

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Biological and clinical implications of cancer stem cells in primary brain tumors. / Maugeri-Saccà, Marcello; Di Martino, Simona; De Maria, Ruggero.

In: Frontiers in Oncology, Vol. 3 JAN, Article 00006, 2013.

Research output: Contribution to journalArticle

@article{71f3d2dc8b184ba6bb58c84d82508955,
title = "Biological and clinical implications of cancer stem cells in primary brain tumors",
abstract = "Despite therapeutic advances, glioblastoma multiforme (GBM) remains a lethal disease. The infiltrative nature of this disease and the presence of a cellular population resistant to current medical treatments account for the poor prognosis of these patients. Growing evidence indicates the existence of a fraction of cancer cells sharing the functional properties of adult stem cells, including self-renewal and a greater ability to escape chemo-radiotherapy-induced death stimuli. Therefore, these cells are commonly defined as cancer stem cells (GBM-SCs). The initial GBM-SC concept has been challenged, and refined according to the emerging molecular taxonomy of GBM. This allowed to postulate the existence of multiple CSC types, each one driving a given molecular entity. Furthermore, it is becoming increasingly clear that GBM-SCs thrive through a dynamic and bidirectional interaction with the surrounding microenvironment. In this article, we discuss recent advances in GBM-SC biology, mechanisms through which these cells adapt to hostile conditions, pharmacological strategies for selectively killing GBM-SCs, and how novel CSC-associated endpoints have been investigated in the clinical setting.",
keywords = "Cancer stem cells, Canonical pathway inhibitors, Chemo-radioresistance, Differentiation-inducing agents, Glioblastoma multiforme, Hypoxia, Self-renewal pathway inhibitors, Stem cell-based endpoints",
author = "Marcello Maugeri-Sacc{\`a} and {Di Martino}, Simona and {De Maria}, Ruggero",
year = "2013",
doi = "10.3389/fonc.2013.00006",
language = "English",
volume = "3 JAN",
journal = "Frontiers in Oncology",
issn = "2234-943X",
publisher = "Frontiers Media S. A.",

}

TY - JOUR

T1 - Biological and clinical implications of cancer stem cells in primary brain tumors

AU - Maugeri-Saccà, Marcello

AU - Di Martino, Simona

AU - De Maria, Ruggero

PY - 2013

Y1 - 2013

N2 - Despite therapeutic advances, glioblastoma multiforme (GBM) remains a lethal disease. The infiltrative nature of this disease and the presence of a cellular population resistant to current medical treatments account for the poor prognosis of these patients. Growing evidence indicates the existence of a fraction of cancer cells sharing the functional properties of adult stem cells, including self-renewal and a greater ability to escape chemo-radiotherapy-induced death stimuli. Therefore, these cells are commonly defined as cancer stem cells (GBM-SCs). The initial GBM-SC concept has been challenged, and refined according to the emerging molecular taxonomy of GBM. This allowed to postulate the existence of multiple CSC types, each one driving a given molecular entity. Furthermore, it is becoming increasingly clear that GBM-SCs thrive through a dynamic and bidirectional interaction with the surrounding microenvironment. In this article, we discuss recent advances in GBM-SC biology, mechanisms through which these cells adapt to hostile conditions, pharmacological strategies for selectively killing GBM-SCs, and how novel CSC-associated endpoints have been investigated in the clinical setting.

AB - Despite therapeutic advances, glioblastoma multiforme (GBM) remains a lethal disease. The infiltrative nature of this disease and the presence of a cellular population resistant to current medical treatments account for the poor prognosis of these patients. Growing evidence indicates the existence of a fraction of cancer cells sharing the functional properties of adult stem cells, including self-renewal and a greater ability to escape chemo-radiotherapy-induced death stimuli. Therefore, these cells are commonly defined as cancer stem cells (GBM-SCs). The initial GBM-SC concept has been challenged, and refined according to the emerging molecular taxonomy of GBM. This allowed to postulate the existence of multiple CSC types, each one driving a given molecular entity. Furthermore, it is becoming increasingly clear that GBM-SCs thrive through a dynamic and bidirectional interaction with the surrounding microenvironment. In this article, we discuss recent advances in GBM-SC biology, mechanisms through which these cells adapt to hostile conditions, pharmacological strategies for selectively killing GBM-SCs, and how novel CSC-associated endpoints have been investigated in the clinical setting.

KW - Cancer stem cells

KW - Canonical pathway inhibitors

KW - Chemo-radioresistance

KW - Differentiation-inducing agents

KW - Glioblastoma multiforme

KW - Hypoxia

KW - Self-renewal pathway inhibitors

KW - Stem cell-based endpoints

UR - http://www.scopus.com/inward/record.url?scp=84890723104&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890723104&partnerID=8YFLogxK

U2 - 10.3389/fonc.2013.00006

DO - 10.3389/fonc.2013.00006

M3 - Article

AN - SCOPUS:84890723104

VL - 3 JAN

JO - Frontiers in Oncology

JF - Frontiers in Oncology

SN - 2234-943X

M1 - Article 00006

ER -